Фактор фон Виллебранда и сердечно-сосудистая патология
DOI:
https://doi.org/10.34687/2219-8202.JAD.2022.04.0002Ключевые слова:
фактор фон Виллебранда, атеросклероз, атеротромбоз, ишемическая болезнь сердцаАннотация
Фактор фон Виллебранда (ФФВ) - большой мультимерный гликопротеин, являющийся одним из компонентов системы гемостаза. При высоких скоростях сдвига, например, в артериях малого диаметра и в местах их выраженного стенозирования, ФФВ играет ключевую роль в адгезии тромбоцитов к субэндотелию при нарушении целостности эндотелиального слоя. ФФВ так же связывается с фактором свертывания крови VIII, являясь его переносчиком в кровотоке и защищая от протеолиза. Дефицит или дисфункция ФФВ предрасполагают к кровотечениям. В то же время, повышенный уровень в крови высокомолекулярных (ВММ) ФФВ тесно ассоциирован с тромботической тромбоцитопенической пурпурой. Наличие тяжелого стеноза устья аорты или гипертрофической кардиомиопатии с обструкцией выносящего тракта левого желудочка может обуславливать возникновение дефицита ВММ ФФВ и, как следствие этому, приводить к криптогенным желудочно-кишечным кровотечениям. Возникновению ишемической болезни сердца (ИБС) и развитию ее осложнений способствует повышенная склонность к тромбообразованию. С учетом участия ФФВ в гемостазе, можно предположить, что нарушение функции этого фактора будет влиять на возникновение и течение ИБС.
Скачивания
Библиографические ссылки
Lancellotti, S., M. Sacco, M. Basso, and R. De Cristofaro, Mechanochemistry of von Willebrand factor. Biomol Concepts, 2019. 10(1): p. 194-208 DOI: 10.1515/bmc-2019-0022.
Chen, J. and D.W. Chung, Inflammation, von Willebrand factor, and ADAMTS13. Blood, 2018. 132(2): p. 141-147 DOI: 10.1182/blood-2018-02-769000.
Lenting, P.J., O.D. Christophe, and C.V. Denis, von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood, 2015. 125(13): p. 2019-28 DOI: 10.1182/blood-2014-06-528406.
Rana, A., E. Westein, B. Niego, and C.E. Hagemeyer, Shear-Dependent Platelet Aggregation: Mechanisms and Therapeutic Opportunities. Front Cardiovasc Med, 2019. 6: p. 141 DOI: 10.3389/fcvm.2019.00141.
Zheng, Y., J. Chen, and J.A. López, Flow-driven assembly of VWF fibres and webs in in vitro microvessels. Nat Commun, 2015. 6: p. 7858 DOI: 10.1038/ncomms8858.
Schneider, S.W., S. Nuschele, A. Wixforth, C. Gorzelanny, A. Alexander-Katz, R.R. Netz, and M.F. Schneider, Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A, 2007. 104(19): p. 7899-903 DOI: 10.1073/pnas.0608422104.
Mannucci, P.M., C. Capoferri, and M.T. Canciani, Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol, 2004. 126(2): p. 213-8 DOI: 10.1111/j.1365-2141.2004.05009.x.
Smith, L.J., Laboratory diagnosis of von Willebrand disease. American Society for Clinical Laboratory Science, 2017. 30(2): p. 65-74.
Horiuchi, H., T. Doman, K. Kokame, Y. Saiki, and M. Matsumoto, Acquired von Willebrand Syndrome Associated with Cardiovascular Diseases. J Atheroscler Thromb, 2019. 26(4): p. 303-314 DOI: 10.5551/jat.RV17031.
Sukumar, S., B. Lämmle, and S.R. Cataland, Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med, 2021. 10(3) DOI: 10.3390/jcm10030536.
James, P.D., N.T. Connell, B. Ameer, J. Di Paola, J. Eikenboom, N. Giraud, S. Haberichter, V. Jacobs-Pratt, B. Konkle, and C. McLintock, ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood advances, 2021. 5(1): p. 280-300.
Roberts, J. and V. Flood, Laboratory diagnosis of v on W illebrand disease. International journal of laboratory hematology, 2015. 37: p. 11-17.
Franchini, M., F. Capra, G. Targher, M. Montagnana, and G. Lippi, Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J, 2007. 5: p. 14 DOI: 10.1186/1477-9560-5-14.
Dörner, K., Klinische Chemie und Hämatologie: 69 Tabellen;[Taschenlehrbuch]. 2009: Georg Thieme Verlag.
Dovlatova, N. and S. Heptinstall, Platelet aggregation measured by single-platelet counting and using PFA-100 devices. Platelets, 2018. 29(7): p. 656-661 DOI: 10.1080/09537104.2018.1492109.
Heyde, E., Gastrointestinal bleeding in aortic stenosis. N Engl J Med, 1958. 259: p. 196.
Warkentin, T.E., J.C. Moore, and D.G. Morgan, Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet, 1992. 340(8810): p. 35-7 DOI: 10.1016/0140-6736(92)92434-h.
Warkentin, T.E., J.C. Moore, and D.G. Morgan, Gastrointestinal angiodysplasia and aortic stenosis. N Engl J Med, 2002. 347(11): p. 858-9 DOI: 10.1056/nejm200209123471122.
Frank, R.D., R. Lanzmich, P.K. Haager, and U. Budde, Severe Aortic Valve Stenosis: sustained cure of acquired von Willebrand syndrome after surgical valve replacement. Clinical and Applied Thrombosis/Hemostasis, 2017. 23(3): p. 229-234.
Yasar, S.J., O. Abdullah, W. Fay, and S. Balla, Von Willebrand factor revisited. J Interv Cardiol, 2018. 31(3): p. 360-367 DOI: 10.1111/joic.12478.
Van Belle, E., F. Vincent, A. Rauch, C. Casari, E. Jeanpierre, V. Loobuyck, M. Rosa, C. Delhaye, H. Spillemaeker, C. Paris, N. Debry, B. Verdier, A. Vincentelli, A. Dupont, P.J. Lenting, and S. Susen, von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week. J Am Coll Cardiol, 2019. 73(9): p. 1078-1088 DOI: 10.1016/j.jacc.2018.12.045.
Panzer, S., R. Badr Eslam, A. Schneller, A. Kaider, D. Koren, B. Eichelberger, R. Rosenhek, U. Budde, and I.M. Lang, Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis. Thromb Haemost, 2010. 103(2): p. 408-14 DOI: 10.1160/th09-06-0391.
Vincentelli, A., S. Susen, T. Le Tourneau, I. Six, O. Fabre, F. Juthier, A. Bauters, C. Decoene, J. Goudemand, A. Prat, and B. Jude, Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med, 2003. 349(4): p. 343-9 DOI: 10.1056/NEJMoa022831.
Blackshear, J.L., Heyde Syndrome: Aortic Stenosis and Beyond. Clin Geriatr Med, 2019. 35(3): p. 369-379 DOI: 10.1016/j.cger.2019.03.007.
Kasai, M., M. Osako, Y. Inaba, K. Yamabe, and M. Aoki, Acquired von Willebrand syndrome secondary to mitral and aortic regurgitation. J Card Surg, 2020. 35(9): p. 2396-2398 DOI: 10.1111/jocs.14796.
Meindl, C., M. Paulus, T. Koller, D. Rogalski, M. Hamerle, C. Schach, S. Buchner, F. Zeman, L.S. Maier, K. Debl, B. Unsöld, and C. Birner, Acquired von Willebrand syndrome and factor VIII in patients with moderate to severe mitral regurgitation undergoing transcatheter mitral valve repair. Clin Cardiol, 2021. 44(2): p. 261-266 DOI: 10.1002/clc.23538.
Blackshear, J.L., H.V. Schaff, S.R. Ommen, D. Chen, and W.L. Nichols, Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy. Mayo Clin Proc, 2011. 86(3): p. 219-24 DOI: 10.4065/mcp.2010.0309.
Le Tourneau, T., S. Susen, C. Caron, A. Millaire, S. Maréchaux, A.S. Polge, A. Vincentelli, F. Mouquet, P.V. Ennezat, N. Lamblin, P. de Groote, E. Van Belle, G. Deklunder, J. Goudemand, C. Bauters, and B. Jude, Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction. Circulation, 2008. 118(15): p. 1550-7 DOI: 10.1161/circulationaha.108.786681.
Rauch, A., S. Susen, and B. Zieger, Acquired von Willebrand Syndrome in Patients With Ventricular Assist Device. Front Med (Lausanne), 2019. 6: p. 7 DOI: 10.3389/fmed.2019.00007.
Mihyawi, N., M. Ajmal, A.R. Fath, B. Bhattarai, and B. Yeneneh, The Cardioprotective Potential of von Willebrand Disease in Ischemic Heart Disease. Texas Heart Institute Journal, 2022. 49(4): p. e207402.
Xu, A.G., R.M. Xu, C.Q. Lu, M.Y. Yao, W. Zhao, X. Fu, J. Guo, Q.F. Xu, and D.D. Li, Correlation of von Willebrand factor gene polymorphism and coronary heart disease. Mol Med Rep, 2012. 6(5): p. 1107-10 DOI: 10.3892/mmr.2012.1037.
Jin, H., Y. Chen, B. Wang, Y. Zhu, L. Chen, X. Han, G. Ma, and N. Liu, Association between brain-derived neurotrophic factor and von Willebrand factor levels in patients with stable coronary artery disease. BMC Cardiovasc Disord, 2018. 18(1): p. 23 DOI: 10.1186/s12872-018-0762-z.
Kaikita, K., K. Soejima, M. Matsukawa, T. Nakagaki, and H. Ogawa, Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost, 2006. 4(11): p. 2490-3 DOI: 10.1111/j.1538-7836.2006.02161.x.
Rutten, B., A. Maseri, D. Cianflone, A. Laricchia, N.A. Cristell, A. Durante, M. Spartera, F. Ancona, L. Limite, D. Hu, H. Li, N.G. Uren, P.G. de Groot, P.M. Mannucci, and M. Roest, Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study. Eur Heart J Acute Cardiovasc Care, 2015. 4(1): p. 64-74 DOI: 10.1177/2048872614534388.
Yan, B., Q. Wang, W. Du, S. Zhai, C. Gou, T. Hu, L. Xia, C. Ruan, and Y. Zhao, Elevated Plasma von Willebrand Factor Antigen and Activity Levels Are Associated With the Severity of Coronary Stenosis. Clin Appl Thromb Hemost, 2020. 26: p. 1076029619900552 DOI: 10.1177/1076029619900552.
Raygan, F., H. Mohammadi, A. Etminan, M. Sehat, and H. Nikoueinejad, Evaluating Serum Levels of Pentraxin-3, von Willebrand Factor and C-X-C Motif Chemokine Ligand 13 as Inflammatory Markers of Unstable Angina Pectoris. Iran J Allergy Asthma Immunol, 2019. 18(2): p. 200-208.
Chion, C.K., C.J. Doggen, J.T. Crawley, D.A. Lane, and F.R. Rosendaal, ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood, 2007. 109(5): p. 1998-2000 DOI: 10.1182/blood-2006-07-038166.
Li, Y., L. Li, F. Dong, L. Guo, Y. Hou, H. Hu, S. Yan, X. Zhou, L. Liao, T.D. Allen, and J.U. Liu, Plasma von Willebrand factor level is transiently elevated in a rat model of acute myocardial infarction. Exp Ther Med, 2015. 10(5): p. 1743-1749 DOI: 10.3892/etm.2015.2721.
Whincup, P.H., J. Danesh, M. Walker, L. Lennon, A. Thomson, P. Appleby, A. Rumley, and G.D. Lowe, von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J, 2002. 23(22): p. 1764-70 DOI: 10.1053/euhj.2001.3237.
Morange, P.E., C. Simon, M.C. Alessi, G. Luc, D. Arveiler, J. Ferrieres, P. Amouyel, A. Evans, P. Ducimetiere, and I. Juhan-Vague, Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation, 2004. 109(11): p. 1343-8 DOI: 10.1161/01.cir.0000120705.55512.ec.
Willeit, P., A. Thompson, T. Aspelund, A. Rumley, G. Eiriksdottir, G. Lowe, V. Gudnason, and E. Di Angelantonio, Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS One, 2013. 8(2): p. e55175 DOI: 10.1371/journal.pone.0055175.
Folsom, A.R., K.K. Wu, W.D. Rosamond, A.R. Sharrett, and L.E. Chambless, Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 1997. 96(4): p. 1102-8 DOI: 10.1161/01.cir.96.4.1102.
Rumley, A., G.D. Lowe, P.M. Sweetnam, J.W. Yarnell, and R.P. Ford, Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol, 1999. 105(1): p. 110-6.
Thögersen, A.M., J.H. Jansson, K. Boman, T.K. Nilsson, L. Weinehall, F. Huhtasaari, and G. Hallmans, High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation, 1998. 98(21): p. 2241-7 DOI: 10.1161/01.cir.98.21.2241.
Smith, F.B., A.J. Lee, F.G. Fowkes, J.F. Price, A. Rumley, and G.D. Lowe, Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol, 1997. 17(11): p. 3321-5 DOI: 10.1161/01.atv.17.11.3321.
Thompson, S.G., J. Kienast, S.D. Pyke, F. Haverkate, and J.C. van de Loo, Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med, 1995. 332(10): p. 635-41 DOI: 10.1056/nejm199503093321003.
Ray, K.K., D.A. Morrow, C.M. Gibson, S. Murphy, E.M. Antman, and E. Braunwald, Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. Eur Heart J, 2005. 26(5): p. 440-6 DOI: 10.1093/eurheartj/ehi104.
Jansson, J.H., T.K. Nilsson, and O. Johnson, von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J, 1991. 66(5): p. 351-5 DOI: 10.1136/hrt.66.5.351.
Tscharre, M., I. Tentzeris, B. Vogel, M.K. Freynhofer, F. Egger, M. Rohla, T.W. Weiss, J. Wojta, K. Huber, S. Farhan, and C. Ay, Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary intervention. Thromb Res, 2020. 196: p. 31-37 DOI: 10.1016/j.thromres.2020.08.018.
Fan, M., X. Wang, X. Peng, S. Feng, J. Zhao, L. Liao, Y. Zhang, Y. Hou, and J. Liu, Prognostic value of plasma von Willebrand factor levels in major adverse cardiovascular events: a systematic review and meta-analysis. BMC Cardiovasc Disord, 2020. 20(1): p. 72 DOI: 10.1186/s12872-020-01375-7.
Danesh, J., J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, G.D. Lowe, M.B. Pepys, and V. Gudnason, C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 2004. 350(14): p. 1387-97 DOI: 10.1056/NEJMoa032804.
Warlo, E.M.K., A.R. Pettersen, H. Arnesen, and I. Seljeflot, vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease. Thromb J, 2017. 15: p. 28 DOI: 10.1186/s12959-017-0151-3.
Price, J.F., P.I. Mowbray, A.J. Lee, A. Rumley, G.D. Lowe, and F.G. Fowkes, Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J, 1999. 20(5): p. 344-53 DOI: 10.1053/euhj.1998.1194.
Blann, A.D., J.E. Brown, and R. Heitmar, Angiogenesis, Metabolism, Endothelial and Platelet Markers in Diabetes and Cardiovascular Disease. Br J Biomed Sci. 2022 Mar 22;79:10313. doi: 10.3389/bjbs.2022.10313. eCollection 2022.
Stehouwer, C.D., J.J. Nauta, G.C. Zeldenrust, W.H. Hackeng, A.J. Donker, and G.J. den Ottolander, Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet, 1992. 340(8815): p. 319-23 DOI: 10.1016/0140-6736(92)91401-s.
Lip, G.Y., A.D. Blann, A.F. Jones, P.L. Lip, and D.G. Beevers, Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol, 1997. 80(12): p. 1566-71 DOI: 10.1016/s0002-9149(97)00749-2.
Vischer, U.M., von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost, 2006. 4(6): p. 1186-93 DOI: 10.1111/j.1538-7836.2006.01949.x.
Kaufmann, J.E., A. Oksche, C.B. Wollheim, G. Günther, W. Rosenthal, and U.M. Vischer, Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest, 2000. 106(1): p. 107-16 DOI: 10.1172/jci9516.
Montalescot, G., F. Philippe, A. Ankri, E. Vicaut, E. Bearez, J.E. Poulard, D. Carrie, D. Flammang, A. Dutoit, A. Carayon, C. Jardel, M. Chevrot, J.P. Bastard, F. Bigonzi, and D. Thomas, Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation, 1998. 98(4): p. 294-9 DOI: 10.1161/01.cir.98.4.294.
Blann, A.D., A. Herrick, and M.I. Jayson, Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol, 1995. 34(9): p. 814-9 DOI: 10.1093/rheumatology/34.9.814.
Nossent, J.C., W.D. Raymond, and G. Eilertsen, Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation. Lupus Sci Med, 2016. 3(1): p. e000162 DOI: 10.1136/lupus-2016-000162.
Kefer, J.M., L.M. Galanti, S. Desmet, V. Deneys, and C.E. Hanet, Time course of release of inflammatory markers after coronary stenting: comparison between bare metal stent and sirolimus-eluting stent. Coron Artery Dis, 2005. 16(8): p. 505-9 DOI: 10.1097/00019501-200512000-00009.
Pottinger, B.E., R.C. Read, E.M. Paleolog, P.G. Higgins, and J.D. Pearson, von Willebrand factor is an acute phase reactant in man. Thromb Res, 1989. 53(4): p. 387-94 DOI: 10.1016/0049-3848(89)90317-4.
Brazilek, R.J., F.J. Tovar-Lopez, A.K.T. Wong, H. Tran, A.S. Davis, J.D. McFadyen, Z. Kaplan, S. Chunilal, S.P. Jackson, H. Nandurkar, A. Mitchell, and W.S. Nesbitt, Application of a strain rate gradient microfluidic device to von Willebrand's disease screening. Lab Chip, 2017. 17(15): p. 2595-2608 DOI: 10.1039/c7lc00498b.
Kim, D.A., K.J. Ashworth, J. Di Paola, and D.N. Ku, Platelet α-granules are required for occlusive high-shear-rate thrombosis. Blood Adv, 2020. 4(14): p. 3258-3267 DOI: 10.1182/bloodadvances.2020002117.
Hosokawa, K., T. Ohnishi, T. Kondo, M. Fukasawa, T. Koide, I. Maruyama, and K.A. Tanaka, A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost, 2011. 9(10): p. 2029-37 DOI: 10.1111/j.1538-7836.2011.04464.x.
Schoeman, R.M., M. Lehmann, and K.B. Neeves, Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders. Platelets, 2017. 28(5): p. 463-471 DOI: 10.1080/09537104.2017.1306042.
Sobel, M., P.M. McNeill, P.L. Carlson, J.C. Kermode, B. Adelman, R. Conroy, and D. Marques, Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest, 1991. 87(5): p. 1787-93 DOI: 10.1172/jci115198.
Kageyama, S., J. Matsushita, and H. Yamamoto, Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol, 2002. 443(1-3): p. 143-9 DOI: 10.1016/s0014-2999(02)01590-x.
Kageyama, S., H. Yamamoto, H. Nakazawa, and R. Yoshimoto, Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res, 2001. 101(5): p. 395-404 DOI: 10.1016/s0049-3848(00)00430-8.
Eto, K., T. Isshiki, H. Yamamoto, S. Takeshita, M. Ochiai, N. Yokoyama, R. Yoshimoto, Y. Ikeda, and T. Sato, AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol, 1999. 19(4): p. 877-82 DOI: 10.1161/01.atv.19.4.877.
Gilbert, J.C., T. DeFeo-Fraulini, R.M. Hutabarat, C.J. Horvath, P.G. Merlino, H.N. Marsh, J.M. Healy, S. Boufakhreddine, T.V. Holohan, and R.G. Schaub, First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation, 2007. 116(23): p. 2678-86 DOI: 10.1161/circulationaha.107.724864.
Markus, H.S., C. McCollum, C. Imray, M.A. Goulder, J. Gilbert, and A. King, The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke, 2011. 42(8): p. 2149-53 DOI: 10.1161/strokeaha.111.616649.
Matsumoto, M. and K. Harada, [Development of a novel aptamer blocking the interaction between the VWF A1 domain and platelet GP Ib for the treatment of arterial thrombosis]. Rinsho Ketsueki, 2022. 63(5): p. 393-402 DOI: 10.11406/rinketsu.63.393.
Sakai, K., T. Someya, K. Harada, H. Yagi, T. Matsui, and M. Matsumoto, Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab. Haematologica, 2020. 105(11): p. 2631-2638 DOI: 10.3324/haematol.2019.235549.
Kovacevic, K.D., N. Buchtele, C. Schoergenhofer, U. Derhaschnig, G. Gelbenegger, C. Brostjan, S. Zhu, J.C. Gilbert, and B. Jilma, The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin. Sci Rep, 2020. 10(1): p. 11180 DOI: 10.1038/s41598-020-68125-9.
Kovacevic, K.D., B. Jilma, S. Zhu, J.C. Gilbert, M.P. Winter, A. Toma, C. Hengstenberg, I. Lang, J. Kubica, and J.M. Siller-Matula, von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo. Thromb Haemost, 2020. 120(9): p. 1282-1290 DOI: 10.1055/s-0040-1713888.
Nimjee, S.M., D. Dornbos, 3rd, G.A. Pitoc, D.G. Wheeler, J.M. Layzer, N. Venetos, A. Huttinger, S.E. Talentino, N.J. Musgrave, H. Moody, R.E. Rempel, C. Jones, K. Carlisle, J. Wilson, C. Bratton, M.E. Joseph, S. Khan, M.R. Hoffman, L. Sommerville, R.C. Becker, J.L. Zweier, and B.A. Sullenger, Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Mol Ther, 2019. 27(7): p. 1228-1241 DOI: 10.1016/j.ymthe.2019.03.016.
Li, T.T., M.L. Fan, S.X. Hou, X.Y. Li, D.M. Barry, H. Jin, S.Y. Luo, F. Kong, L.F. Lau, X.R. Dai, G.H. Zhang, and L.L. Zhou, A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury. Br J Pharmacol, 2015. 172(15): p. 3904-16 DOI: 10.1111/bph.13178.
Chu, W., X. Sun, X. Zhu, Y.C. Zhao, J. Zhang, Q. Kong, and L. Zhou, Blockade of platelet glycoprotein receptor Ib ameliorates blood-brain barrier disruption following ischemic stroke via Epac pathway. Biomed Pharmacother, 2021. 140: p. 111698 DOI: 10.1016/j.biopha.2021.111698.
Li, B.X., X. Dai, X.R. Xu, R. Adili, M.A.D. Neves, X. Lei, C. Shen, G. Zhu, Y. Wang, H. Zhou, Y. Hou, T. Ni, Y. Pasman, Z. Yang, F. Qian, Y. Zhao, Y. Gao, J. Liu, M. Teng, A.H. Marshall, E.G. Cerenzia, M.L. Li, and H. Ni, In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα. Sci Rep, 2021. 11(1): p. 11663 DOI: 10.1038/s41598-021-91165-8.
Zheng, B., J. Li, J. Jiang, D. Xiang, Y. Chen, Z. Yu, H. Zeng, J. Ge, X. Dai, J. Liu, B. Li, and Y. Huo, Safety and efficacy of a platelet glycoprotein Ib inhibitor for patients with non-ST segment elevation myocardial infarction: A phase Ib/IIa study. Pharmacotherapy, 2021. 41(10): p. 828-836 DOI: 10.1002/phar.2620.
Scully, M., S.R. Cataland, F. Peyvandi, P. Coppo, P. Knöbl, J.A. Kremer Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, F. Callewaert, D. Biswas, H. De Winter, and R.K. Zeldin, Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med, 2019. 380(4): p. 335-346 DOI: 10.1056/NEJMoa1806311.
van Loon, J.E., P.P. de Jaegere, H. Ulrichts, H.H. van Vliet, M.P. de Maat, P.G. de Groot, M.L. Simoons, and F.W. Leebeek, The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thromb Haemost, 2011. 106(1): p. 165-71 DOI: 10.1160/th10-12-0804.
Bartunek, J., E. Barbato, K. Vercruysse, C. Duby, W. Wijns, G. Heyndrickx, and J.-B. Holz, Safety and efficacy of anti-von Willebrand Factor Nanobody® ALX-0081 in stable angina patients undergoing percutaneous coronary intervention. 2010, Am Heart Assoc.
Bartunek, J., E. Barbato, G. Heyndrickx, M. Vanderheyden, W. Wijns, and J.B. Holz, Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor. J Cardiovasc Transl Res, 2013. 6(3): p. 355-63 DOI: 10.1007/s12265-012-9435-y.
Witsch, T., K. Martinod, N. Sorvillo, I. Portier, S.F. De Meyer, and D.D. Wagner, Recombinant Human ADAMTS13 Treatment Improves Myocardial Remodeling and Functionality After Pressure Overload Injury in Mice. J Am Heart Assoc, 2018. 7(3) DOI: 10.1161/jaha.117.007004.
De Meyer, S.F., A.S. Savchenko, M.S. Haas, D. Schatzberg, M.C. Carroll, A. Schiviz, B. Dietrich, H. Rottensteiner, F. Scheiflinger, and D.D. Wagner, Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood, 2012. 120(26): p. 5217-23 DOI: 10.1182/blood-2012-06-439935.
Goebel, S., Z. Li, J. Vogelmann, H.P. Holthoff, H. Degen, D.M. Hermann, M. Gawaz, M. Ungerer, and G. Münch, The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. PLoS One, 2013. 8(7): p. e66960 DOI: 10.1371/journal.pone.0066960.
Mayer, K., R. Hein-Rothweiler, S. Schüpke, M. Janisch, I. Bernlochner, G. Ndrepepa, D. Sibbing, T. Gori, O. Borst, S. Holdenrieder, D. Kupka, T. Petzold, C. Bradaric, R. Okrojek, D.M. Leistner, T.D. Trippel, T. Münzel, U. Landmesser, B. Pieske, A.M. Zeiher, M.P. Gawaz, A. Hapfelmeier, K.L. Laugwitz, H. Schunkert, A. Kastrati, and S. Massberg, Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. JAMA Cardiol, 2021. 6(7): p. 753-761 DOI: 10.1001/jamacardio.2021.0475.
Gröschel, K., T. Uphaus, I. Loftus, H. Poppert, H.C. Diener, J. Zobel, and G. Münch, Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial. TH Open, 2020. 4(4): p. e393-e399 DOI: 10.1055/s-0040-1721078.
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2022 С. Д. Охота, С. Г. Козлов, Ю. Н. Автаева, И. С. Мельников, З. А. Габбасов
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
